Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Insulin Resistance Associated Disorders Pivoting Long-Term Hepatitis B Surface Antigen Decline During Entecavir Therapy.

Lin TC, Liu WC, Hsu YH, Lin JJ, Chiu YC, Chiu HC, Cheng PN, Chen CY, Chang TT, Wu IC.

J Clin Med. 2019 Nov 6;8(11). pii: E1892. doi: 10.3390/jcm8111892.

2.

Trajectories of serum hepatitis B surface antigen kinetics in patients with chronic hepatitis B receiving long-term nucleos(t)ide analogue therapy.

Hsu WF, Chen CF, Lai HC, Su WP, Lin CH, Chuang PH, Chen SH, Chen CH, Wang HW, Huang GT, Peng CY.

Liver Int. 2018 Apr;38(4):627-635. doi: 10.1111/liv.13564. Epub 2017 Sep 15.

PMID:
28857411
3.

Long-term outcome of entecavir treatment of nucleos(t)ide analogue-naïve chronic hepatitis B patients in Japan.

Suzuki F, Hosaka T, Suzuki Y, Sezaki H, Akuta N, Fujiyama S, Kawamura Y, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Mineta R, Suzuki Y, Kumada H.

J Gastroenterol. 2019 Feb;54(2):182-193. doi: 10.1007/s00535-018-1502-y. Epub 2018 Aug 22.

PMID:
30136216
4.

Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy.

Li N, Xu JH, Yu M, Wang S, Si CW, Yu YY.

World J Gastroenterol. 2015 Nov 21;21(43):12421-9. doi: 10.3748/wjg.v21.i43.12421.

5.

Clinical utility of hepatitis B surface antigen kinetics in treatment-naïve chronic hepatitis B patients during long-term entecavir therapy.

Lin TC, Chiu YC, Chiu HC, Liu WC, Cheng PN, Chen CY, Chang TT, Wu IC.

World J Gastroenterol. 2018 Feb 14;24(6):725-736. doi: 10.3748/wjg.v24.i6.725.

6.

Changes of HBsAg and interferon-inducible protein 10 serum levels in naive HBeAg-negative chronic hepatitis B patients under 4-year entecavir therapy.

Papatheodoridis G, Goulis J, Manolakopoulos S, Margariti A, Exarchos X, Kokkonis G, Hadziyiannis E, Papaioannou C, Manesis E, Pectasides D, Akriviadis E.

J Hepatol. 2014 Jan;60(1):62-8. doi: 10.1016/j.jhep.2013.08.023. Epub 2013 Sep 6.

PMID:
24012614
7.

Sequential combination therapy with pegylated interferon leads to loss of hepatitis B surface antigen and hepatitis B e antigen (HBeAg) seroconversion in HBeAg-positive chronic hepatitis B patients receiving long-term entecavir treatment.

Li GJ, Yu YQ, Chen SL, Fan P, Shao LY, Chen JZ, Li CS, Yi B, Chen WC, Xie SY, Mao XN, Zou HH, Zhang WH.

Antimicrob Agents Chemother. 2015 Jul;59(7):4121-8. doi: 10.1128/AAC.00249-15. Epub 2015 May 4.

8.

Changes of HBsAg and HBV DNA levels in Chinese chronic hepatitis B patients after 5 years of entecavir treatment.

Seto WK, Lam YF, Fung J, Wong DK, Huang FY, Hung IF, Lai CL, Yuen MF.

J Gastroenterol Hepatol. 2014 May;29(5):1028-34. doi: 10.1111/jgh.12476.

PMID:
24325451
9.

Hepatitis B s antigen kinetics during treatment with nucleos(t)ides analogues in patients with hepatitis B e antigen-negative chronic hepatitis B.

Striki A, Manolakopoulos S, Deutsch M, Kourikou A, Kontos G, Kranidioti H, Hadziyannis E, Papatheodoridis G.

Liver Int. 2017 Nov;37(11):1642-1650. doi: 10.1111/liv.13432. Epub 2017 Apr 26.

PMID:
28345181
10.

Pretreatment serum HBsAg-to-HBV DNA ratio predicts a virologic response to entecavir in chronic hepatitis B.

Song JC, Min BY, Kim JW, Kim JY, Kim YM, Shin CM, Lee SH, Hwang JH, Jeong SH, Kim N, Lee DH.

Korean J Hepatol. 2011 Dec;17(4):268-73. doi: 10.3350/kjhep.2011.17.4.268.

11.

Long-term entecavir therapy results in falls in serum hepatitis B surface antigen levels and seroclearance in nucleos(t)ide-naïve chronic hepatitis B patients.

Hara T, Suzuki F, Kawamura Y, Sezaki H, Hosaka T, Akuta N, Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Watahiki S, Mineta R, Kumada H.

J Viral Hepat. 2014 Nov;21(11):802-8. doi: 10.1111/jvh.12211. Epub 2013 Dec 16.

PMID:
25274427
12.

Reduction of hepatitis B surface antigen and covalently closed circular DNA by nucleos(t)ide analogues of different potency.

Wong DK, Seto WK, Fung J, Ip P, Huang FY, Lai CL, Yuen MF.

Clin Gastroenterol Hepatol. 2013 Aug;11(8):1004-10.e1. doi: 10.1016/j.cgh.2013.01.026. Epub 2013 Feb 1.

PMID:
23376799
13.

A long-term multicenter study: Entecavir versus Tenofovir in treatment of nucleos(t)ide analogue-naive chronic hepatitis B patients.

Kayaaslan B, Akinci E, Ari A, Tufan ZK, Alpat SN, Gunal O, Tosun S, Guner R, Tabak F.

Clin Res Hepatol Gastroenterol. 2018 Feb;42(1):40-47. doi: 10.1016/j.clinre.2017.06.008. Epub 2017 Jul 27.

PMID:
28757048
14.

Treatment cessation of entecavir in Asian patients with hepatitis B e antigen negative chronic hepatitis B: a multicentre prospective study.

Seto WK, Hui AJ, Wong VW, Wong GL, Liu KS, Lai CL, Yuen MF, Chan HL.

Gut. 2015 Apr;64(4):667-72. doi: 10.1136/gutjnl-2014-307237. Epub 2014 May 15.

PMID:
24833635
15.

Patterns of hepatitis B surface antigen decline and HBV DNA suppression in Asian treatment-experienced chronic hepatitis B patients after three years of tenofovir treatment.

Seto WK, Liu K, Wong DK, Fung J, Huang FY, Hung IF, Lai CL, Yuen MF.

J Hepatol. 2013 Oct;59(4):709-16. doi: 10.1016/j.jhep.2013.06.007. Epub 2013 Jun 17.

PMID:
23792029
16.

Stratification of hepatocellular carcinoma risk through modified FIB-4 index in chronic hepatitis B patients on entecavir therapy.

Wang HW, Lai HC, Hu TH, Su WP, Lu SN, Lin CH, Hung CH, Chuang PH, Wang JH, Lee MH, Chen CH, Peng CY.

J Gastroenterol Hepatol. 2019 Feb;34(2):442-449. doi: 10.1111/jgh.14372. Epub 2018 Jul 19.

PMID:
29968933
17.

Kinetics and prediction of HBsAg loss during long-term therapy with nucleos(t)ide analogues of different potency in patients with chronic hepatitis B.

Li MR, Xi HL, Wang QH, Hou FQ, Huo N, Zhang XX, Li F, Xu XY.

PLoS One. 2014 Jun 6;9(6):e98476. doi: 10.1371/journal.pone.0098476. eCollection 2014.

18.

α-Fetoprotein level-dependent early hepatitis B surface antigen decline during entecavir therapy in chronic hepatitis B with hepatitis flare.

Jeng WJ, Chen YC, Chang ML, Liaw YF.

J Antimicrob Chemother. 2016 Jun;71(6):1601-8. doi: 10.1093/jac/dkw019. Epub 2016 Mar 2.

PMID:
26936920
19.

Quantification of HBsAg in nucleos(t)ide-naïve patients treated for chronic hepatitis B with entecavir with or without tenofovir in the BE-LOW study.

Zoulim F, Carosi G, Greenbloom S, Mazur W, Nguyen T, Jeffers L, Brunetto M, Yu S, Llamoso C.

J Hepatol. 2015 Jan;62(1):56-63. doi: 10.1016/j.jhep.2014.08.031. Epub 2014 Aug 28.

PMID:
25176615
20.

Predictive value of interferon-gamma inducible protein 10 kD for hepatitis B e antigen clearance and hepatitis B surface antigen decline during pegylated interferon alpha therapy in chronic hepatitis B patients.

Wang Y, Zhao C, Zhang L, Yu W, Shen C, Wang W, Zhen Z, Zhou J.

Antiviral Res. 2014 Mar;103:51-9. doi: 10.1016/j.antiviral.2014.01.001. Epub 2014 Jan 10.

PMID:
24418572

Supplemental Content

Support Center